JP4646907B2 - 2−アミノベンゾイル誘導体 - Google Patents

2−アミノベンゾイル誘導体 Download PDF

Info

Publication number
JP4646907B2
JP4646907B2 JP2006516814A JP2006516814A JP4646907B2 JP 4646907 B2 JP4646907 B2 JP 4646907B2 JP 2006516814 A JP2006516814 A JP 2006516814A JP 2006516814 A JP2006516814 A JP 2006516814A JP 4646907 B2 JP4646907 B2 JP 4646907B2
Authority
JP
Japan
Prior art keywords
diseases
hydrogen
pharmaceutically acceptable
aminobenzoyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006516814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007518673A (ja
JP2007518673A5 (cg-RX-API-DMAC7.html
Inventor
ナヴァ・ジサペル
モシェ・ラウドン
ドヴォラー・デイリー
Original Assignee
ニューリム ファーマシューティカルズ(1991)リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューリム ファーマシューティカルズ(1991)リミテッド filed Critical ニューリム ファーマシューティカルズ(1991)リミテッド
Publication of JP2007518673A publication Critical patent/JP2007518673A/ja
Publication of JP2007518673A5 publication Critical patent/JP2007518673A5/ja
Application granted granted Critical
Publication of JP4646907B2 publication Critical patent/JP4646907B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
JP2006516814A 2003-06-26 2004-06-24 2−アミノベンゾイル誘導体 Expired - Fee Related JP4646907B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL15666903A IL156669A0 (en) 2003-06-26 2003-06-26 2-aminobenzoyl derivatives
PCT/IL2004/000567 WO2004112690A2 (en) 2003-06-26 2004-06-24 2-aminobenzoyl derivatives

Publications (3)

Publication Number Publication Date
JP2007518673A JP2007518673A (ja) 2007-07-12
JP2007518673A5 JP2007518673A5 (cg-RX-API-DMAC7.html) 2007-08-23
JP4646907B2 true JP4646907B2 (ja) 2011-03-09

Family

ID=32587677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006516814A Expired - Fee Related JP4646907B2 (ja) 2003-06-26 2004-06-24 2−アミノベンゾイル誘導体

Country Status (31)

Country Link
US (1) US8309767B2 (cg-RX-API-DMAC7.html)
EP (1) EP1644316B1 (cg-RX-API-DMAC7.html)
JP (1) JP4646907B2 (cg-RX-API-DMAC7.html)
KR (1) KR101115196B1 (cg-RX-API-DMAC7.html)
CN (1) CN1835910B (cg-RX-API-DMAC7.html)
AR (1) AR044786A1 (cg-RX-API-DMAC7.html)
AT (1) ATE460391T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004249012B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0411382A (cg-RX-API-DMAC7.html)
CA (1) CA2527112C (cg-RX-API-DMAC7.html)
CY (1) CY1110043T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004025937D1 (cg-RX-API-DMAC7.html)
DK (1) DK1644316T3 (cg-RX-API-DMAC7.html)
EA (1) EA011255B1 (cg-RX-API-DMAC7.html)
ES (1) ES2341958T3 (cg-RX-API-DMAC7.html)
HN (1) HN2004000224A (cg-RX-API-DMAC7.html)
IL (1) IL156669A0 (cg-RX-API-DMAC7.html)
IS (1) IS8235A (cg-RX-API-DMAC7.html)
MX (1) MXPA06000022A (cg-RX-API-DMAC7.html)
NO (1) NO20060420L (cg-RX-API-DMAC7.html)
NZ (1) NZ544908A (cg-RX-API-DMAC7.html)
PA (1) PA8605401A1 (cg-RX-API-DMAC7.html)
PE (1) PE20050230A1 (cg-RX-API-DMAC7.html)
PL (1) PL1644316T3 (cg-RX-API-DMAC7.html)
PT (1) PT1644316E (cg-RX-API-DMAC7.html)
SI (1) SI1644316T1 (cg-RX-API-DMAC7.html)
TW (1) TWI342210B (cg-RX-API-DMAC7.html)
UA (1) UA85187C2 (cg-RX-API-DMAC7.html)
UY (1) UY28382A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004112690A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200600640B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1869002A (zh) * 2005-05-27 2006-11-29 中国科学院上海药物研究所 一类非甾体雄激素受体调节剂、其制备方法和用途
US7622495B2 (en) * 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
EP2922847A1 (en) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
WO2016027757A1 (ja) * 2014-08-18 2016-02-25 国立大学法人大阪大学 新規2-アミノベンゾイル誘導体
JP6836044B2 (ja) * 2015-03-05 2021-02-24 国立大学法人 東京医科歯科大学 長期記憶誘導剤
US11712425B2 (en) 2018-03-14 2023-08-01 Albert Einstein College Of Medicine Immunoregulatory role of 3-OH-kynurenamine and uses thereof
US11911376B2 (en) 2020-03-30 2024-02-27 The Regents Of The University Of Colorado Methods for preventing and treating retinal damage
WO2026004785A1 (ja) * 2024-06-25 2026-01-02 ロート製薬株式会社 組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT305987B (de) 1969-12-18 1973-03-26 Degussa Verfahren zur Herstellung von neuen Aminoketonen
GB1334884A (en) * 1970-12-18 1973-10-24 Sumitomo Chemical Co Aminoalcohols and their conversion to aminoketones
JPS5336455B2 (cg-RX-API-DMAC7.html) * 1973-02-03 1978-10-03
US4018823A (en) * 1976-04-20 1977-04-19 Morton-Norwich Products, Inc. 4',5'-Dimethoxy-2',3-diaminopropiophenone dihydrochloride
FR2569185B1 (fr) * 1984-08-20 1986-09-05 Lafon Labor Derives de 1-(aminophenyl)-2-amino-ethanone, procede de preparation et utilisation en therapeutique

Also Published As

Publication number Publication date
EA011255B1 (ru) 2009-02-27
AU2004249012B2 (en) 2010-04-01
EP1644316B1 (en) 2010-03-10
PL1644316T3 (pl) 2010-08-31
EA200600115A1 (ru) 2008-06-30
NZ544908A (en) 2009-11-27
ZA200600640B (en) 2007-05-30
UY28382A1 (es) 2004-11-08
PE20050230A1 (es) 2005-04-22
TWI342210B (en) 2011-05-21
WO2004112690B1 (en) 2005-05-19
TW200503672A (en) 2005-02-01
KR20060023581A (ko) 2006-03-14
MXPA06000022A (es) 2006-07-06
EP1644316A4 (en) 2006-10-25
UA85187C2 (en) 2009-01-12
KR101115196B1 (ko) 2012-02-24
AR044786A1 (es) 2005-10-05
US8309767B2 (en) 2012-11-13
PT1644316E (pt) 2010-06-02
HK1094795A1 (en) 2007-04-13
CN1835910B (zh) 2010-09-29
ATE460391T1 (de) 2010-03-15
JP2007518673A (ja) 2007-07-12
NO20060420L (no) 2006-01-25
WO2004112690A3 (en) 2005-03-17
WO2004112690A2 (en) 2004-12-29
IS8235A (is) 2006-01-16
CN1835910A (zh) 2006-09-20
BRPI0411382A (pt) 2006-09-19
PA8605401A1 (es) 2006-03-24
DE602004025937D1 (de) 2010-04-22
IL156669A0 (en) 2004-01-04
CA2527112C (en) 2012-08-21
DK1644316T3 (da) 2010-07-19
CY1110043T1 (el) 2015-01-14
SI1644316T1 (sl) 2010-06-30
HN2004000224A (es) 2007-12-21
ES2341958T3 (es) 2010-06-30
CA2527112A1 (en) 2004-12-29
US20060270733A1 (en) 2006-11-30
AU2004249012A1 (en) 2004-12-29
EP1644316A2 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
JP2025102814A (ja) 発毛を調節するための組成物及び方法
JP2009543872A (ja) 選択的アンドロゲン受容体調節薬、その類似体及び誘導体とそれらの使用
US20210113557A1 (en) Methods of treating prostate cancer
JP2019507111A (ja) 代謝抵抗性フェンフルラミン類縁体およびその使用法
JP2010505816A (ja) 治療薬剤としての置換アリール−インドール化合物とそのキヌレニン/キヌラミン様代謝産物
JP2022504697A (ja) Ssao阻害剤とその使用
JP6175054B2 (ja) ヒストンアセチルトランスフェラーゼ活性剤の使用
JP4874489B2 (ja) Comt阻害剤の鎮痛剤としての用途
JP2007518673A (ja) 2−アミノベンゾイル誘導体
JP2021518347A (ja) ペルオキシソーム増殖因子活性化受容体アルファのアゴニストおよび使用方法
JP2015518887A (ja) 神経疾患の予防方法
JP2007518673A5 (cg-RX-API-DMAC7.html)
HK1094795B (en) 2-aminobenzoyl derivatives
JP3513876B2 (ja) メラトニン作用性類似物としてのインドール誘導体
US20250099436A1 (en) Drug for treating tinnitus
JP2001522360A (ja) 神経保護性化合物およびその使用
JP2005509673A (ja) 新規な医薬化合物
JP2020511427A (ja) 新規の芳香族化合物
HK40086070A (en) Compositions and methods for modulating hair growth
JPWO2000053563A1 (ja) 核内リセプターpparの新規リガンド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100915

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101015

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101116

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101207

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131217

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees